SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*
Harrison Seth Loring

(Last) (First) (Middle)
C/O STOKE THERAPEUTICS, INC.
45 WIGGINS AVENUE

(Street)
BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading Symbol
Stoke Therapeutics, Inc. [STOK]

3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
X Director
10% Owner
Officer (give title below)
Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	$28.8	07/16/2026		G(1)			29,555	(2)	09/09/2029	Common Stock	29,555	$0	0	D	
Stock Option (Right to Buy)	$28.8	07/16/2026		G(1)		29,555		(2)	09/09/2029	Common Stock	29,555	$0	29,555	I	By Trust(3)
Stock Option (Right to Buy)	$26.53	07/16/2026		G(1)			14,777	(4)	06/02/2030	Common Stock	14,777	$0	0	D	
Stock Option (Right to Buy)	$26.53	07/16/2026		G(1)		14,777		(4)	06/02/2030	Common Stock	14,777	$0	14,777	I	By Trust(3)
Stock Option (Right to Buy)	$40.37	07/16/2026		G(1)			11,650	(5)	06/07/2031	Common Stock	11,650	$0	0	D	
Stock Option (Right to Buy)	$40.37	07/16/2026		G(1)		11,650		(5)	06/07/2031	Common Stock	11,650	$0	11,650	I	By Trust(3)
Stock Option (Right to Buy)	$12.96	07/16/2026		G(1)			21,000	(6)	06/06/2032	Common Stock	21,000	$0	0	D	
Stock Option (Right to Buy)	$12.96	07/16/2026		G(1)		21,000		(6)	06/06/2032	Common Stock	21,000	$0	21,000	I	By Trust(3)
Stock Option (Right to Buy)	$12.46	07/16/2026		G(1)			19,441	(7)	06/12/2033	Common Stock	19,441	$0	0	D	
Stock Option (Right to Buy)	$12.46	07/16/2026		G(1)		19,441		(7)	06/12/2033	Common Stock	19,441	$0	19,441	I	By Trust(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	$16.41	07/16/2026		G[1]			7,639	[8]	06/04/2034	Common Stock	7,639	$0	0	D	
Stock Option (Right to Buy)	$16.41	07/16/2026		G[1]		7,639		[8]	06/04/2034	Common Stock	7,639	$0	7,639	I	By Trust[3]
Stock Option (Right to Buy)	$10.9	07/16/2026		G[1]			29,747	[9]	06/02/2035	Common Stock	29,747	$0	0	D	
Stock Option (Right to Buy)	$10.9	07/16/2026		G[1]		29,747		[9]	06/02/2035	Common Stock	29,747	$0	29,747	I	By Trust[3]
Stock Option (Right to Buy)	$29.46	07/16/2026		G[1]			17,786	[10]	06/02/2036	Common Stock	17,786	$0	0	D	
Stock Option (Right to Buy)	$29.46	07/16/2026		G[1]		17,786		[10]	06/02/2036	Common Stock	17,786	$0	17,786	I	By Trust[3]

Explanation of Responses:

1. The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended.

2. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on March 21, 2022.

3. The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust.

4. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2021.

5. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 8, 2022.

6. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 7, 2023.

7. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 13, 2024.

8. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2025.

9. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2026.

10. The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the Issuer on the vesting date.

/s/ Jonathan Allan, Attorney-in-Fact	07/17/2026
** Signature of Reporting Person	Date